Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

In stark contrast to the often adversarial U.S. perspective, the European biopharma community increasingly views China as a strategic partner. The focus is not on competition but on integration, leveraging China as a "force multiplier" for global drug development and commercialization, highlighting a significant divergence in geopolitical business strategy.

An understanding of cultural perspectives on medicine, such as the preference for injectables in Asia versus tablets elsewhere, is crucial for designing and positioning products for successful global launches. This insight often gets overlooked by scientifically-focused development teams.

BeiGene's success demonstrates a new model for biotech growth. It started in China and expanded globally, but critically maintains China as a core hub for innovation. This challenges the traditional view that biotech innovation flows primarily from the West and must be built from a US headquarters.

Roche’s massive global footprint of diagnostic instruments makes them the default partner for pharma companies developing companion diagnostics. This expands the test menu on their platforms, which in turn makes the instruments indispensable for labs, creating a powerful, self-reinforcing competitive advantage.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

Enviva employs a bifurcated global strategy. It leverages China's efficient talent pool and rapid clinical trial system for early discovery and proof-of-concept. It then shifts to the US and Europe for full-scale manufacturing and late-stage clinical development to gain "golden standard" regulatory approval and global market access.

Beyond a supportive ecosystem, CDR Life's CEO highlights Switzerland's dense concentration of well-trained life science professionals from big pharma, biotech, and top universities as its most critical advantage. This makes it easier to hire and retain the specialized talent essential for a biotech's success.